PTC Stock Recent News

WARREN, N.J. , June 21, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nine new employees.

--New App Empowers Engineers and Designers to Validate Manufacturability, Optimize Designs, and Accelerate Speed to Market-- --Leverages Proprietary Artificial Intelligence (AI) Algorithms-- ITASCA, Ill. , June 10, 2024 /PRNewswire/ -- SyBridge Technologies, a global leader in design and manufacturing solutions, today announced the launch of SyBridge Studio, a state-of-the-art manufacturing insights application, now available on the PTC Onshape® App Store.

PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?

WARREN, N.J. , May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Annual Growth Stock Conference Tuesday, June 4, at 9:00 am ET / 8:00 am CT The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.

- Review of European marketing application for PKU now initiated - WARREN, N.J. , May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.

PTC's performance gains from solid momentum across the PLM and CAD business segments.

- European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J. , May 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation.

PTC's new CEO has reset growth expectations to a more realistic level. The company's secular growth prospects are great, and a better economic environment will lead to larger deals.

PTC's fiscal second-quarter performance benefits from steady demand for its computer-aided design and product lifecycle management solutions.

While the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.